Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Treatment Strategies Against Psoriasis: Principle, Perspectives and Practices

Author(s): Arya Kadukkattil Ramanunny, Sheetu Wadhwa, Sachin Kumar Singh*, Deep Shikha Sharma, Rubiya Khursheed and Ankit Awasthi

Volume 17, Issue 1, 2020

Page: [52 - 73] Pages: 22

DOI: 10.2174/1567201816666191120120551

Price: $65

conference banner
Abstract

Background: Psoriasis is a genetically predisposed autoimmune disease mediated by cytokines released by the activated immune cells. It manifests inflammatory, scaly red or white silvery flaky skin which may be a fluid-filled lesion with soreness and itchiness. The prevalence rate of psoriasis is increasing day by day. Despite having such a high prevalence rate, the treatment of psoriasis is still limited. Hence, there is a need to rethink the various treatment strategies available in the allopathic as well as in the alternative systems of medicine.

Methods: Various bibliographic databases of previously published peer-reviewed research papers were explored and systematic data culminated in terms of various treatment strategies used for the management of psoriasis. The prime focus is given towards modern as well as alternative systems of medicine such as phototherapy, a combination of phototherapy with pharmacotherapy such as Ayurveda, Yoga and naturopathy, Unani, Siddha, and Homeopathy to treat psoriasis.

Results: A comprehensive review of 161 papers, including both research and review articles, was carried out to make the article readily understandable. The pathogenesis including inflammatory mediators and type of psoriasis is discussed before the treatment strategies to understand the pathophysiology of the disease. The uniqueness, procedure, advantages, and limitations of conventional, advanced, and traditional systems of medicine to treat psoriasis are discussed in detail. Emphasis has also been given towards marine sources such as fish oil, marine sponges, and algae.

Conclusion: Although there are many modern and alternative treatment strategies available to treat psoriasis, none of them have been proven to provide complete relief to patients. Moreover, they are associated with certain side effects. In order to overcome them, novel drug delivery systems have been utilized and found effective; however, their stability and safety become the major impediments towards their successful positioning. Traditional and alternative treatment strategies have found to be safe and effective but their use is localized to certain areas. In a nutshell, to achieve successful treatment of psoriasis, there is a need to focus on the development of stable and non-toxic novel drug delivery systems or the promotion of traditional systems to treat psoriasis.

Keywords: Psoriasis, novel drug delivery systems, phototherapy, alternative systems, marine sources, homeopathy.

« Previous Next »
Graphical Abstract

[1]
Dev, K.; Sahoo, D.R.P.K.; Shahi, D.S. Psoriasis: A review. Int. J. Pharm. Sci. Res., 2017, 2(3), 46-51.
[2]
Takeshita, J.; Grewal, S.; Langan, S.M.; Mehta, N.N.; Ogdie, A.; Van Voorhees, A.S.; Gelfand, J.M. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol., 2017, 76(3), 377-390.
[http://dx.doi.org/10.1016/j.jaad.2016.07.064] [PMID: 28212759]
[3]
Li, K.; Armstrong, A.W. A review of health outcomes in patients with psoriasis. Dermatol. Clin., 2012, 30(1), 61-72, viii..
[http://dx.doi.org/10.1016/j.det.2011.08.012] [PMID: 22117868]
[4]
World Psoriasis Day, 2018.https://ifpa-pso.com/our-actions/world-psoriasis-day
[5]
Global report on psoriasis, http://www.apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf
[6]
Rapalli, V.K.; Singhvi, G.; Dubey, S.K.; Gupta, G.; Chellappan, D.K.; Dua, K. Emerging landscape in psoriasis management: From topical application to targeting biomolecules. Biomed. Pharmacother., 2018, 106, 707-713.
[http://dx.doi.org/10.1016/j.biopha.2018.06.136] [PMID: 29990862]
[7]
https://www.valueinhealthjournal.com/article/S1098-3015(14)01733-1/pdf
[8]
Gelfand, J.M.; Stern, R.S.; Nijsten, T.; Feldman, S.R.; Thomas, J.; Kist, J.; Rolstad, T.; Margolis, D.J. The prevalence of psoriasis in African Americans: Results from a population-based study. J. Am. Acad. Dermatol., 2005, 52(1), 23-26.
[http://dx.doi.org/10.1016/j.jaad.2004.07.045] [PMID: 15627076]
[9]
Leder, R.O.; Farber, E.M. The variable incidence of psoriasis in sub-Saharan Africa. Int. J. Dermatol., 1997, 36(12), 911-919.
[http://dx.doi.org/10.1046/j.1365-4362.1997.00251.x] [PMID: 9466197]
[10]
Schleicher, S.M. Psoriasis: Pathogenesis, assessment, and therapeutic update. Clin. Podiatr. Med. Surg., 2016, 33(3), 355-366.
[http://dx.doi.org/10.1016/j.cpm.2016.02.004] [PMID: 27215156]
[11]
Web, M.D. Types of psoriasis, available from: https://www. webmd.com/skin-problems-and-treatments/psoriasis/ss/types-of-psoriasis
[12]
Dogra, S.; Yadav, S. Psoriasis in India: prevalence and pattern. Indian J. Dermatol. Venereol. Leprol., 2010, 76(6), 595-601.
[http://dx.doi.org/10.4103/0378-6323.72443] [PMID: 21079301]
[13]
Boutet, M.A.; Nerviani, A.; Gallo Afflitto, G.; Pitzalis, C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. Int. J. Mol. Sci., 2018, 19(2), 530.
[http://dx.doi.org/10.3390/ijms19020530] [PMID: 29425183]
[14]
Lowes, M.A.; Bowcock, A.M.; Krueger, J.G. Pathogenesis and therapy of psoriasis. Nature, 2007, 445(7130), 866-873.
[http://dx.doi.org/10.1038/nature05663] [PMID: 17314973]
[15]
Lee, C.H.; Hwang, S.T.Y. Pathophysiology of chemokines and chemokine receptors in dermatological science: A focus on psoriasis and cutaneous T-cell lymphoma. Zhonghua Pifuke Yixue Zazhi, 2012, 30(4), 128-135.
[http://dx.doi.org/10.1016/j.dsi.2012.08.004]
[16]
Mahajan, R.; Handa, S. Pathophysiology of psoriasis. Indian J. Dermatol. Venereol. Leprol., 2013, 79(7)(Suppl. 7), S1-S9.
[http://dx.doi.org/10.4103/0378-6323.115505] [PMID: 23974689]
[17]
Gudjonsson, J.E.; Karason, A.; Runarsdottir, E.H.; Antonsdottir, A.A.; Hauksson, V.B.; Jónsson, H.H.; Gulcher, J.; Stefansson, K.; Valdimarsson, H. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C- and HLA-B-typed patients. J. Invest. Dermatol., 2006, 126(4), 740-745.
[http://dx.doi.org/10.1038/sj.jid.5700118] [PMID: 16439971]
[18]
Prieto-Pérez, R.; Cabaleiro, T.; Daudén, E.; Ochoa, D.; Roman, M.; Abad-Santos, F. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis., 2013., 2013613086
[http://dx.doi.org/10.1155/2013/613086] [PMID: 24069534]
[19]
Alshobaili, H.A.; Shahzad, M.; Al-Marshood, A.; Khalil, A.; Settin, A.; Barrimah, I. Genetic background of psoriasis. Int. J. Health Sci. (Qassim), 2010, 4(1), 23-29.
[PMID: 21475522]
[20]
Chandra, A.; Senapati, S.; Roy, S.; Chatterjee, G.; Chatterjee, R. Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clin. Epigenetics, 2018, 10(1), 108.
[http://dx.doi.org/10.1186/s13148-018-0541-9] [PMID: 30092825]
[21]
Zeng, J.; Luo, S.; Huang, Y.; Lu, Q. Critical role of environmental factors in the pathogenesis of psoriasis. J. Dermatol., 2017, 44(8), 863-872.
[http://dx.doi.org/10.1111/1346-8138.13806] [PMID: 28349593]
[22]
Schaarschmidt, M.L.; Schmieder, A.; Umar, N.; Terris, D.; Goebeler, M.; Goerdt, S.; Peitsch, W.K. Patient preferences for psoriasis treatments: Process characteristics can outweigh outcome attributes. Arch. Dermatol., 2011, 147(11), 1285-1294.
[http://dx.doi.org/10.1001/archdermatol.2011.309] [PMID: 22106115]
[23]
Dogra, S.; Bishnoi, A. Childhood psoriasis: What is new and what is news. Indian J. Paediatr. Dermatol., 2018, 19(4), 308.
[http://dx.doi.org/10.4103/ijpd.IJPD_72_18]
[24]
Slutsky, J.B.; Clark, R.A.; Remedios, A.A.; Klein, P.A. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J. Drugs Dermatol., 2010, 9(10), 1258-1264.
[PMID: 20941951]
[25]
Schoket, B.; Horkay, I.; Kósa, A.; Páldeák, L.; Hewer, A.; Grover, P.L.; Phillips, D.H. Formation of DNA adducts in the skin of psoriasis patients, in human skin in organ culture, and in mouse skin and lung following topical application of coal-tar and juniper tar. J. Invest. Dermatol., 1990, 94(2), 241-246.
[http://dx.doi.org/10.1111/1523-1747.ep12874576] [PMID: 2299199]
[26]
Gelmetti, C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am. J. Clin. Dermatol., 2009, 10(Suppl. 1), 7-12.
[http://dx.doi.org/10.2165/0128071-200910001-00002] [PMID: 19209948]
[27]
Nola, I.; Kostović, K.; Kotrulja, L.; Lugović, L. The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenerol. Croat., 2003, 11(2), 80-87.
[PMID: 12773264]
[28]
Runne, U.; Kunze, J. Short-duration (‘minutes’) therapy with dithranol for psoriasis: A new out-patient regimen. Br. J. Dermatol., 1982, 106(2), 135-139.
[http://dx.doi.org/10.1111/j.1365-2133.1982.tb00922.x] [PMID: 7059509]
[29]
Fluhr, J.W.; Cavallotti, C.; Berardesca, E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin. Dermatol., 2008, 26(4), 380-386.
[http://dx.doi.org/10.1016/j.clindermatol.2008.01.015] [PMID: 18691519]
[30]
Reynolds, N.J.; Al-Daraji, W.I. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin. Exp. Dermatol., 2002, 27(7), 555-561.
[http://dx.doi.org/10.1046/j.1365-2230.2002.01148.x] [PMID: 12464150]
[31]
Duvic, M.; Nagpal, S.; Asano, A.T.; Chandraratna, R.A. Molecular mechanisms of tazarotene action in psoriasis. J. Am. Acad. Dermatol., 1997, 37(2 Pt 3), S18-S24.
[http://dx.doi.org/10.1016/S0190-9622(97)80396-9] [PMID: 9270552]
[32]
Weinstein, G.D.; Koo, J.Y.; Krueger, G.G.; Lebwohl, M.G.; Lowe, N.J.; Menter, M.A.; Lew-Kaya, D.A.; Sefton, J.; Gibson, J.R.; Walker, P.S. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J. Am. Acad. Dermatol., 2003, 48(5), 760-767.
[http://dx.doi.org/10.1067/mjd.2003.103] [PMID: 12734506]
[33]
Kwatra, G. Mukhopadhyay, S. Topical Corticosteroids: Pharmacology. A Treatise on Topical Corticosteroids in Dermatology; Springer: Singapore, 2018, pp. 11-22.
[http://dx.doi.org/10.1007/978-981-10-4609-4_2]
[34]
National Psoriasis foundation. What’s top in topical steroid treatment? Available from: https://www.psoriasis.org/about-psoriasis/treatments/topicals/steroids/potency-chart
[35]
Mehta, A.B.; Nadkarni, N.J.; Patil, S.P.; Godse, K.V.; Gautam, M.; Agarwal, S. Topical corticosteroids in dermatology. Indian J. Dermatol. Venereol. Leprol., 2016, 82(4), 371-378.
[http://dx.doi.org/10.4103/0378-6323.178903] [PMID: 27279294]
[36]
Gerritsen, M.J.; Van De Kerkhof, P.C.; Langner, A. Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br. J. Dermatol., 2001, 144(Suppl. 58), 17-19.
[PMID: 11501508]
[37]
Hegyi, Z.; Zwicker, S.; Bureik, D.; Peric, M.; Koglin, S.; Batycka-Baran, A.; Prinz, J.C.; Ruzicka, T.; Schauber, J.; Wolf, R. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 “alarmins” psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J. Invest. Dermatol., 2012, 132(5), 1416-1424.
[http://dx.doi.org/10.1038/jid.2011.486] [PMID: 22402441]
[38]
Mahajan, B.B.; Singla, M. Evaluation of intralesional 5% 5-fluorouracil in resistant localized plaque psoriasis. Indian Dermatol. Online J., 2014, 5(3), 287-290.
[http://dx.doi.org/10.4103/2229-5178.137779] [PMID: 25165645]
[39]
Tsuji, T.; Sugai, T. Topically administered fluorouracil in psoriasis. Arch. Dermatol., 1972, 105(2), 208-212.
[http://dx.doi.org/10.1001/archderm.1972.01620050022003] [PMID: 5060863]
[40]
Zhang, P.; Wu, M.X. A clinical review of phototherapy for psoriasis. Lasers Med. Sci., 2018, 33(1), 173-180.
[http://dx.doi.org/10.1007/s10103-017-2360-1] [PMID: 29067616]
[41]
Lebwohl, M.; Feldman, S.R.; Walther, R.; Shelk, J.; Morgan, P.; Gutkin, S.W. Clinical management of psoriasis: Principles and practice. Cutis, 2001, 67(1)(Suppl.), 1-15.
[PMID: 11210296]
[42]
Feldman, S.R.; Duffin, K.C. Treatment of psoriasis in adults., 2017. Available from: https://www.uptodate.com/contents/treatment-of-psoriasis-in-adults
[43]
Weinstein, G.D.; Goldfaden, G.; Frost, P. Methotrexate. Mechanism of action on DNA synthesis in psoriasis. Arch. Dermatol., 1971, 104(3), 236-243.
[http://dx.doi.org/10.1001/archderm.1971.04000210010003] [PMID: 5096831]
[44]
Warren, R.B.; Griffiths, C.E. Systemic therapies for psoriasis: Methotrexate, retinoids, and cyclosporine. Clin. Dermatol., 2008, 26(5), 438-447.
[http://dx.doi.org/10.1016/j.clindermatol.2007.11.006] [PMID: 18755362]
[45]
Thappa, D.M.; Laxmisha, C. Immunomodulators in the treatment of psoriasis. Indian J. Dermatol. Venereol. Leprol., 2004, 70(1), 1-9.
[PMID: 17642548]
[46]
Lim, K.K.; Su, W.P.; Schroeter, A.L.; Sabers, C.J.; Abraham, R.T.; Pittelkow, M.R. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin. Proc., 1996, 71(12), 1182-1191.
[http://dx.doi.org/10.4065/71.12.1182] [PMID: 8945493]
[47]
Saurat, J.H. Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment. J. Am. Acad. Dermatol., 1999, 41(3 Pt 2), S2-S6.
[http://dx.doi.org/10.1016/S0190-9622(99)70358-0] [PMID: 10459139]
[48]
Carretero, G.; Ribera, M.; Belinchón, I.; Carrascosa, J.M.; Puig, L.; Ferrandiz, C.; Dehesa, L.; Vidal, D.; Peral, F.; Jorquera, E.; González-Quesada, A.; Muñoz, C.; Notario, J.; Vanaclocha, F.; Moreno, J.C. Guidelines for the use of acitretin in psoriasis. Actas Dermosifiliogr., 2013, 104(7), 598-616.
[http://dx.doi.org/10.1016/j.adengl.2013.01.001] [PMID: 23891453]
[49]
Lee, C.S.; Koo, J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin. Pharmacother., 2005, 6(10), 1725-1734.
[http://dx.doi.org/10.1517/14656566.6.10.1725] [PMID: 16086658]
[50]
Schafer, P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem. Pharmacol., 2012, 83(12), 1583-1590.
[http://dx.doi.org/10.1016/j.bcp.2012.01.001] [PMID: 22257911]
[51]
Ortiz-Ibáñez, K.; Alsina, M.M.; Muñoz-Santos, C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr., 2013, 104(4), 304-310.
[http://dx.doi.org/10.1016/j.adengl.2013.03.002] [PMID: 23583515]
[52]
García-Caballero, M.; Marí-Beffa, M.; Medina, M.A.; Quesada, A.R. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: A possible role for its antipsoriatic effect? J. Invest. Dermatol., 2011, 131(6), 1347-1355.
[http://dx.doi.org/10.1038/jid.2010.416] [PMID: 21289642]
[53]
Mrowietz, U.; Christophers, E.; Altmeyer, P. Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. Br. J. Dermatol., 1999, 141(3), 424-429.
[http://dx.doi.org/10.1046/j.1365-2133.1999.03034.x] [PMID: 10584060]
[54]
Usmani, S.S.; Bedi, G.; Samuel, J.S.; Singh, S.; Kalra, S.; Kumar, P.; Ahuja, A.A.; Sharma, M.; Gautam, A.; Raghava, G.P.S. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS One, 2017, 12(7)e0181748
[http://dx.doi.org/10.1371/journal.pone.0181748] [PMID: 28759605]
[55]
Jenneck, C.; Novak, N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther. Clin. Risk Manag., 2007, 3(3), 411-420.
[PMID: 18488075]
[56]
Krueger, G.G.; Papp, K.A.; Stough, D.B.; Loven, K.H.; Gulliver, W.P.; Ellis, C.N.; Group, A.C.S. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol., 2002, 47(6), 821-833.
[http://dx.doi.org/10.1067/mjd.2002.127247] [PMID: 12451365]
[57]
Zaghi, D.; Krueger, G.G.; Callis Duffin, K. Ustekinumab: A review in the treatment of plaque psoriasis and psoriatic arthritis. J. Drugs Dermatol., 2012, 11(2), 160-167.
[PMID: 22270196]
[58]
Gniadecki, R.; Bang, B.; Bryld, L.E.; Iversen, L.; Lasthein, S.; Skov, L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br. J. Dermatol., 2015, 172(1), 244-252.
[http://dx.doi.org/10.1111/bjd.13343] [PMID: 25132294]
[59]
Gottlieb, A.B.; Chamian, F.; Masud, S.; Cardinale, I.; Abello, M.V.; Lowes, M.A.; Chen, F.; Magliocco, M.; Krueger, J.G. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol., 2005, 175(4), 2721-2729.
[http://dx.doi.org/10.4049/jimmunol.175.4.2721] [PMID: 16081850]
[60]
Tyring, S.; Gordon, K.B.; Poulin, Y.; Langley, R.G.; Gottlieb, A.B.; Dunn, M.; Jahreis, A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Dermatol., 2007, 143(6), 719-726.
[http://dx.doi.org/10.1001/archderm.143.6.719] [PMID: 17576937]
[61]
Jeon, C.; Sekhon, S.; Yan, D.; Afifi, L.; Nakamura, M.; Bhutani, T. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Hum. Vaccin. Immunother., 2017, 13(10), 2247-2259.
[http://dx.doi.org/10.1080/21645515.2017.1356498] [PMID: 28825875]
[62]
http://www.ccras.nic.in/sites/default/files/viewpdf/faq/PSORIASIS. pdf
[63]
https://www.kottakkal.shop/blogs/healing-with-kottakkalayurveda/ ayyappala-coconut-skin-oil-highlight
[64]
http://www.oushadhi.org/page.php?slug=product-details&pid=8
[65]
Psoriasis self management. Yoga for psoriasis: Deep breathing http://www.psoriasisselfmanagement.com/detoxification-ideas/yoga-for-psoriasis-deep-breathing/
[66]
Available from: http://www.psoriasisselfmanagement.com/detoxification-ideas/yoga-for-psoriasis-deep-breathing/
[67]
Available from: http://www.naturopathycure.com/naturopathy-treatment-for-psoriasis.php
[68]
Lebwohl, M.; Ting, P.T.; Koo, J.Y.M. Psoriasis treatment: Traditional therapy. Ann. Rheum. Dis., 2005, 64(Suppl. 2), ii83-ii86.
[http://dx.doi.org/10.1136/ard.2004.030791] [PMID: 15708945]
[69]
Lebwohl, M.; Ali, S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J. Am. Acad. Dermatol., 2001, 45(4), 487-498.
[http://dx.doi.org/10.1067/mjd.2001.117046] [PMID: 11568737]
[70]
Ahmad, Z. Role of Unani (Greek) therapy in the treatment of psoriasis -Case series. IOSR: JDMS, 2016, 15(9), 24-27.
[http://dx.doi.org/10.9790/0853-1509122427]
[71]
Saranya, M.S.; Mustafa, M.M. Anti-bacterial activity of siddha polyherbomineral drug Gandhagarasayanam. Int. J. Curr. Res. Biol. Med., 2017, 2(10), 19-23.
[72]
National institute of Siddha. Available from: http://nischennai. org/siddha-success-stories-nis-psoriasis-kaalaanjagapadai.html
[73]
Alam, M.; Joy, S.; Purushothaman, K.K.; Muthy, J.R.; Anandan, T.; Veluchamy, G. Preparation of “777 oil” used for psoriasis in siddha medicine by modified method. Anc. Sci. Life, 1988, 8(1), 17-19.
[PMID: 22557623]
[74]
Nwabudike, L.C. Psoriasis and homeopathy., 2011.
[75]
Meng, S.; Lin, Z.; Wang, Y.; Wang, Z.; Li, P.; Zheng, Y. Psoriasis therapy by Chinese medicine and modern agents. Chin. Med., 2018, 13(1), 16.
[http://dx.doi.org/10.1186/s13020-018-0174-0] [PMID: 29588654]
[76]
Wang, M.; Sui, S.; Gong, A.; Guan, Y.; Kuang, X. Efficacy of Yinxieling ointment on 675 cases. Chin. Tradit. Patent. Med., 1990, 12(11), 21.
[77]
Shi, Q.; Shengshun, T.; Zhiping, S.; An, Z.J.; Yi, Y.J.; Ping, L. Clinical study on Huoxuesanyuxiaoyin decoction for treating psoriasis vulgaris with blood stasis syndrome. J. Chin. Med. Mater, 2005, 5, 442-444.
[78]
Chen, H.X.J.; Zhang, Y. Effects of curcuma on expression of CD45RO, VEGF and iNOS in psoriatic lesions. Chin. J. Dermato. Venerol. Integ. Trad. W. Med, 2004, 3(4), 198-201.
[79]
Cho, J.W.; Lee, K.S.; Kim, C.W. Curcumin attenuates the expression of IL-1β, IL-6, and TNF-α as well as cyclin E in TNF-α-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int. J. Mol. Med., 2007, 19(3), 469-474.
[http://dx.doi.org/10.3892/ijmm.19.3.469] [PMID: 17273796]
[80]
Xie, X. Effects of Liangxuejiedu formula and indigo on the activation of KC/γδT involved CCL20 in psoriasis model. Master’s Thesis, Beijing University of Chinese Medicine, China 2017.
[81]
Zhao, J.; Di, T.; Wang, Y.; Wang, Y.; Liu, X.; Liang, D.; Li, P. Paeoniflorin inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response and cytokine secretion. Eur. J. Pharmacol., 2016, 772, 131-143.
[http://dx.doi.org/10.1016/j.ejphar.2015.12.040] [PMID: 26738780]
[82]
Di, T.T.; Ruan, Z.T.; Zhao, J.X.; Wang, Y.; Liu, X.; Wang, Y.; Li, P. Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway. Int. Immunopharmacol., 2016, 32, 32-38.
[http://dx.doi.org/10.1016/j.intimp.2015.12.035] [PMID: 26784569]
[83]
Wang, Y.; Zhao, J.; Di, T.; Wang, M.; Ruan, Z.; Zhang, L.; Xie, X.; Meng, Y.; Lin, Y.; Liu, X.; Wang, N.; Li, P. Suppressive effect of β,β-dimethylacryloyl alkannin on activated dendritic cells in psoriasis by the TLR7/8 pathway. Int. Immunopharmacol., 2016, 40, 410-418.
[http://dx.doi.org/10.1016/j.intimp.2016.09.029] [PMID: 27697724]
[84]
Zheng, M.R.; Xie, Y.; Zhang, R.Z. Preliminary study on baicalin treatment for psoriasis vulgaris. Zhongguo Pifu Xingbingxue Zazhi, 1990, 4, 217-218.
[85]
Wu, J.; Li, H.; Li, M. Effects of baicalin cream in two mouse models: 2,4-dinitrofluorobenzene-induced contact hypersensitivity and mouse tail test for psoriasis. Int. J. Clin. Exp. Med., 2015, 8(2), 2128-2137.
[PMID: 25932143]
[86]
Wang, Y.N.; Bi, X.L.; Gu, J.; Gao, S.Q. Study on the mechanism of baicalin in psoriasis treatment. Chin. J. Integr. Med., 2003, 2, 209-211.
[87]
Bi, X.L.; Wang, Y.N.; Gu, J.; Gao, S.Q. Effect of baicalin on the iNOS expression in fibroblasts. Zhonghua Pifuke Zazhi, 2004, 37, 112-113.
[88]
Zhang, J.; Liu, H.Y.; Yu, X.J. Efects of baicalin on proliferation and expression of IL-8 in culture HaCaT keratinocyte. J. Taishan Med. Coll., 2006, 27, 326-327.
[89]
Dwarampudi, L.P.; Palaniswamy, D.; Nithyanantham, M.; Raghu, P.S. Antipsoriatic activity and cytotoxicity of ethanolic extract of Nigella sativa seeds. Pharmacogn. Mag., 2012, 8(32), 268-272.
[http://dx.doi.org/10.4103/0973-1296.103650] [PMID: 24082629]
[90]
Lin, Z.X.; Jiao, B.W.; Che, C.T.; Zuo, Z.; Mok, C.F.; Zhao, M.; Ho, W.K.; Tse, W.P.; Lam, K.Y.; Fan, R.Q.; Yang, Z.J.; Cheng, C.H. Ethyl acetate fraction of the root of Rubia cordifolia L. inhibits keratinocyte proliferation in vitro and promotes keratinocyte differentiation in vivo: Potential application for psoriasis treatment. Phytother. Res., 2010, 24(7), 1056-1064.
[PMID: 19960426]
[91]
Vijayalakshmi, A.; Ravichandiran, V.; Malarkodi, V.; Nirmala, S.; Jayakumari, S. Screening of flavonoid “quercetin” from the rhizome of Smilax china Linn. for anti-psoriatic activity. Asian Pac. J. Trop. Biomed., 2012, 2(4), 269-275.
[http://dx.doi.org/10.1016/S2221-1691(12)60021-5] [PMID: 23569912]
[92]
Shrivastav, S.; Sindhu, R.; Kumar, S.; Kumar, P. Anti-psoriatic and phytochemical evaluation of Thespesia populnea bark extracts. Int J. Pharm. Pharm. Sci., 2009, 1(sup 1), 176-185.
[93]
Singhal, M.; Kansara, N. Cassia tora Linn cream inhibits ultraviolet-B-induced psoriasis in rats. ISRN Dermatol., 2012. 2012346510
[http://dx.doi.org/10.5402/2012/346510] [PMID: 22536527]
[94]
Oyedeji, F.O.; Bankole-Ojo, O.S. Quantitative evaluation of the antipsoriatic activity of sausage tree (Kigeliaafricana). Afr. J. Pure Appl. Chem., 2012, 6(13), 214-218.
[95]
Herman, A.; Herman, A.P. Topically used herbal products for the treatment of psoriasis-mechanism of action, drug delivery, clinical studies. Planta Med., 2016, 82(17), 1447-1455.
[http://dx.doi.org/10.1055/s-0042-115177] [PMID: 27574899]
[96]
Jin, H.L.; Zhang, R.Z.; Gao, Y.X. Effect of artesunate on keratinocyte cultured in vitro. Chin. J. Trad. Med. Sci. Tech., 2007, 14, 176-178.
[97]
Huang, T.; Lin, X. Effects of camptothecin on proliferation and differentiation of keratinizing epithelium. Zhongguo Pifu Xingbingxue Zazhi, 1996, 10, 325-327.
[98]
Traub, M.; Marshall, K. Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. Altern. Med. Rev., 2007, 12(4), 319-330.
[PMID: 18069901]
[99]
Kalyan Kumar, G.; Dhamotharan, R.; Kulkarni, N.M.; Mahat, M.Y.; Gunasekaran, J.; Ashfaque, M. Embelin reduces cutaneous TNF-α level and ameliorates skin edema in acute and chronic model of skin inflammation in mice. Eur. J. Pharmacol., 2011, 662(1-3), 63-69.
[http://dx.doi.org/10.1016/j.ejphar.2011.04.037] [PMID: 21549694]
[100]
Harries, M.J.; Chalmers, R.J.; Griffiths, C.E. Fumaric acid esters for severe psoriasis: A retrospective review of 58 cases. Br. J. Dermatol., 2005, 153(3), 549-551.
[http://dx.doi.org/10.1111/j.1365-2133.2005.06728.x] [PMID: 16120141]
[101]
Dodou, K.; Anderson, R.J.; Lough, W.J.; Small, D.A.P.; Shelley, M.D.; Groundwater, P.W. Synthesis of gossypol atropisomers and derivatives and evaluation of their anti-proliferative and anti-oxidant activity. Bioorg. Med. Chem., 2005, 13(13), 4228-4237.
[http://dx.doi.org/10.1016/j.bmc.2005.04.026] [PMID: 15878283]
[102]
Kamuhabwa, A.R.; Roelandts, R.; de Witte, P.A. Skin photosensitization with topical hypericin in hairless mice. J. Photochem. Photobiol. B, 1999, 53(1-3), 110-114.
[http://dx.doi.org/10.1016/S1011-1344(99)00135-9] [PMID: 10672536]
[103]
Lin, J.; Liu, X.; Bao, Y.; Hou, S.; An, L.; Lin, X. Effects of isocamptothecin, a novel camptothecin analogue, on proliferation, apoptosis and telomerase activity in HaCaT cells. Exp. Dermatol., 2008, 17(6), 530-536.
[http://dx.doi.org/10.1111/j.1600-0625.2007.00674.x] [PMID: 18218022]
[104]
Zhang, L.L.; Huang, C.Q.; Zhang, Z.Y.; Wang, Z.R.; Lin, J.M. [Therapeutic effects of koumine on psoriasis: An experimental study in mice] J. First Mil. Med. Univ., 2005, 25(5), 547-549.
[PMID: 15897131]
[105]
Briffa, D.V.; Warin, A.P. Photochemotherapy in psoriasis: A review. J. R. Soc. Med., 1979, 72(6), 440-446.
[http://dx.doi.org/10.1177/014107687907200610] [PMID: 399641]
[106]
Pazyar, N.; Yaghoobi, R. Tea tree oil as a novel antipsoriasis weapon. Skin Pharmacol. Physiol., 2012, 25(3), 162-163.
[http://dx.doi.org/10.1159/000337936] [PMID: 22473218]
[107]
Carson, C.F.; Hammer, K.A.; Riley, T.V. Melaleuca alternifolia (Tea Tree) oil: A review of antimicrobial and other medicinal properties. Clin. Microbiol. Rev., 2006, 19(1), 50-62.
[http://dx.doi.org/10.1128/CMR.19.1.50-62.2006] [PMID: 16418522]
[108]
Nadjib Boukhatem, M.; Kameli, A.; Amine Ferhat, M.; Saidi, F.; Mekarnia, M. Rose geranium essential oil as a source of new and safe anti-inflammatory drugs. Libyan J. Med., 2013, 8(1), 22520.
[http://dx.doi.org/10.3402/ljm.v8i0.22520] [PMID: 28156234]
[109]
Prashar, A.; Locke, I.C.; Evans, C.S. Cytotoxicity of lavender oil and its major components to human skin cells. Cell Prolif., 2004, 37(3), 221-229.
[http://dx.doi.org/10.1111/j.1365-2184.2004.00307.x] [PMID: 15144499]
[110]
Cavanagh, H.M.A.; Wilkinson, J.M. Biological activities of lavender essential oil. Phytother. Res., 2002, 16(4), 301-308.
[http://dx.doi.org/10.1002/ptr.1103] [PMID: 12112282]
[111]
https://www.healthline.com/health/essential-oils-for-psoriasis#coconut-oil
[112]
Puglia, C.; Tropea, S.; Rizza, L.; Santagati, N.A.; Bonina, F. In vitro percutaneous absorption studies and in vivo evaluation of anti-inflammatory activity of essential fatty acids (EFA) from fish oil extracts. Int. J. Pharm., 2005, 299(1-2), 41-48.
[http://dx.doi.org/10.1016/j.ijpharm.2005.04.031] [PMID: 15979259]
[113]
Amigó, M.; Payá, M.; De Rosa, S.; Terencio, M.C. Antipsoriatic effects of avarol-3′-thiosalicylate are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin. Br. J. Pharmacol., 2007, 152(3), 353-365.
[http://dx.doi.org/10.1038/sj.bjp.0707394] [PMID: 17641670]
[114]
de Caralt, S.; Sánchez-Fontenla, J.; Uriz, M.J.; Wijffels, R.H. In situ aquaculture methods for Dysidea avara (Demospongiae, Porifera) in the northwestern Mediterranean. Mar. Drugs, 2010, 8(6), 1731-1742.
[http://dx.doi.org/10.3390/md8061731] [PMID: 20631865]
[115]
Tommonaro, G.; Iodice, C. The Mediterranean sponge Dysideaavara as a 40 year inspiration of marine natural product chemists. J. Biodiversity and Endangered Species, 2015, 2015.
[116]
Rodríguez-Luna, A.; Talero, E. Terencio.; Gnzález-Rodríguez, M.;Rabasco, A.; de los Reyes, C.; Ávila-Román, J. Topical application of Glycolipids from isochrysisgalbana prevents epidermal hyperplasia in mice. Mar. Drugs, 2017, 16(1), 2.
[http://dx.doi.org/10.3390/md16010002] [PMID: 29295585]
[117]
Pradhan, M.; Singh, D.; Singh, M.R. Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches. J. Control. Release, 2013, 170(3), 380-395.
[http://dx.doi.org/10.1016/j.jconrel.2013.05.020] [PMID: 23770117]
[118]
Torchilin, V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release, 2001, 73(2-3), 137-172.
[http://dx.doi.org/10.1016/S0168-3659(01)00299-1] [PMID: 11516494]
[119]
Mishra, I. Dendrimer: A novel drug delivery system. J. Drug Deliv. Ther., 2011, 1(2)
[http://dx.doi.org/10.22270/jddt.v1i2.46]
[120]
Amin, S.; Rajabnezhad, S.; Kohli, K. Hydrogels as potential drug delivery systems. Sci. Res. Essays, 2009, 4(11), 1175-1183.
[121]
Singh, D.; Rawat Singh, M.; Saraf, S.; Dixit, V.K.; Saraf, S. Formulation optimization of metronidazole loaded chitosan microspheres for wound management by 3-Factor, 3-level box-behnken design. Micro Nanosyst., 2010, 2(2), 70-77.
[http://dx.doi.org/10.2174/1876402911002020070]
[122]
Carino, G.P.; Jacob, J.S.; Mathiowitz, E. Nanosphere based oral insulin delivery. J. Control. Release, 2000, 65(1-2), 261-269.
[http://dx.doi.org/10.1016/S0168-3659(99)00247-3] [PMID: 10699286]
[123]
Letchford, K.; Burt, H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm., 2007, 65(3), 259-269.
[http://dx.doi.org/10.1016/j.ejpb.2006.11.009] [PMID: 17196803]
[124]
Cevc, G.; Blume, G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim. Biophys. Acta, 1992, 1104(1), 226-232.
[http://dx.doi.org/10.1016/0005-2736(92)90154-E] [PMID: 1550849]
[125]
Verma, D.D.; Verma, S.; Blume, G.; Fahr, A. Particle size of liposomes influences dermal delivery of substances into skin. Int. J. Pharm., 2003, 258(1-2), 141-151.
[http://dx.doi.org/10.1016/S0378-5173(03)00183-2] [PMID: 12753761]
[126]
Madhav, N.V.S.; Saini, A. Niosomes: A novel drug delivery system. Int. J. Res. Pharm. Chem., 2011, 1(3), 498-511.
[127]
Dubey, V.; Mishra, D.; Dutta, T.; Nahar, M.; Saraf, D.K.; Jain, N.K. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J. Control. Release, 2007, 123(2), 148-154.
[http://dx.doi.org/10.1016/j.jconrel.2007.08.005] [PMID: 17884226]
[128]
Ekambaram, P.; Sathali, A.A.H.; Priyanka, K. Solid lipid nanoparticles: A review. Sci. Rev. Chem. Commun., 2012, 2(1), 80-102.
[129]
Xia, Q.; Saupe, A.; Müller, R.H.; Souto, E.B. Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int. J. Cosmet. Sci., 2007, 29(6), 473-482.
[http://dx.doi.org/10.1111/j.1468-2494.2007.00410.x] [PMID: 18489386]
[130]
Gupta, S.; Moulik, S.P. Biocompatible microemulsions and their prospective uses in drug delivery. J. Pharm. Sci., 2008, 97(1), 22-45.
[http://dx.doi.org/10.1002/jps.21177] [PMID: 17887122]
[131]
Baboota, S.; Alam, M.S.; Sharma, S.; Sahni, J.K.; Kumar, A.; Ali, J. Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int. J. Pharm. Investig., 2011, 1(3), 139-147.
[http://dx.doi.org/10.4103/2230-973X.85963] [PMID: 23071936]
[132]
Wan, T.; Pan, J.; Long, Y.; Yu, K.; Wang, Y.; Pan, W.; Ruan, W.; Qin, M.; Wu, C.; Xu, Y. Dual roles of TPGS based microemulsion for tacrolimus: Enhancing the percutaneous delivery and anti-psoriatic efficacy. Int. J. Pharm., 2017, 528(1-2), 511-523.
[http://dx.doi.org/10.1016/j.ijpharm.2017.06.050] [PMID: 28629978]
[133]
Benigni, M.; Pescina, S.; Grimaudo, M.A.; Padula, C.; Santi, P.; Nicoli, S. Development of microemulsions of suitable viscosity for cyclosporine skin delivery. Int. J. Pharm., 2018, 545(1-2), 197-205.
[http://dx.doi.org/10.1016/j.ijpharm.2018.04.049] [PMID: 29698819]
[134]
Behera, J.; Keservani, R.K.; Yadav, A.; Tripathi, M.; Chadoker, A. Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis. Int. J. Drug Deliv., 2010, 2(2)
[http://dx.doi.org/10.5138/ijdd.2010.0975.0215.02025]
[135]
Musa, S.H.; Basri, M.; Fard Masoumi, H.R.; Shamsudin, N.; Salim, N. Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: In vitro diffusion and in vivo hydrating action. Int. J. Nanomedicine, 2017, 12, 2427-2441.
[http://dx.doi.org/10.2147/IJN.S125302] [PMID: 28405165]
[136]
Rajitha, P.; Shammika, P.; Aiswarya, S.; Gopikrishnan, A.; Jayakumar, R.; Sabitha, M. Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J. Drug Deliv. Sci. Technol., 2019, 49, 463-476.
[http://dx.doi.org/10.1016/j.jddst.2018.12.020]
[137]
Pund, S.; Pawar, S.; Gangurde, S.; Divate, D. Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity. Int. J. Pharm., 2015, 487(1-2), 148-156.
[http://dx.doi.org/10.1016/j.ijpharm.2015.04.015] [PMID: 25869452]
[138]
Panonnummal, R.; Sabitha, M. Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model. Int. J. Biol. Macromol., 2018, 110, 245-258.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.10.112] [PMID: 29054520]
[139]
Barradas, T.N.; Senna, J.P.; Cardoso, S.A.; de Holanda, E. Silva, K.G.; Elias Mansur, C.R. Formulation characterization and in vitro drug release of hydrogel-thickened nanoemulsions for topical delivery of 8-methoxypsoralen. Mater. Sci. Eng. C, 2018, 92, 245-253.
[http://dx.doi.org/10.1016/j.msec.2018.06.049] [PMID: 30184748]
[140]
Kaur, A.; Katiyar, S.S.; Kushwah, V.; Jain, S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine (Lond.), 2017, 13(4), 1473-1482.
[http://dx.doi.org/10.1016/j.nano.2017.02.009] [PMID: 28259803]
[141]
Alam, M.S.; Ali, M.S.; Alam, N.; Alam, M.I.; Anwer, T.; Imam, F.; Shamim, M. Design and characterization of nanostructure topical gel of betamethasone dipropionate for psoriasis. J. Appl. Pharm. Sci., 2012, 2(10), 148.
[http://dx.doi.org/10.1016/j.nano.2017.02.009]
[142]
Somagoni, J.; Boakye, C.H.; Godugu, C.; Patel, A.R.; Mendonca Faria, H.A.; Zucolotto, V.; Singh, M. Nanomiemgel--a novel drug delivery system for topical application--in vitro and in vivo evaluation. PLoS One, 2014, 9(12)e115952
[http://dx.doi.org/10.1371/journal.pone.0115952] [PMID: 25546392]
[143]
Divya, G.; Panonnummal, R.; Gupta, S.; Jayakumar, R.; Sabitha, M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur. J. Pharm. Biopharm., 2016, 107, 97-109.
[http://dx.doi.org/10.1016/j.ejpb.2016.06.019] [PMID: 27368748]
[144]
Pradhan, M.; Singh, D.; Singh, M.R. Fabrication, optimization and characterization of triamcinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis: Application of box behnken design, in vitro and ex vivo studies. J. Drug Deliv. Sci. Technol., 2017, 41, 325-333.
[http://dx.doi.org/10.1016/j.jddst.2017.07.024]
[145]
Tripathi, P.; Kumar, A.; Jain, P.K.; Patel, J.R. Carbomer gel bearing methotrexate loaded lipid nanocontainers shows improved topical delivery intended for effective management of psoriasis. Int. J. Biol. Macromol., 2018, 120(Pt A), 1322-1334.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.08.136] [PMID: 30171962]
[146]
Pinto, M.F.; Moura, C.C.; Nunes, C.; Segundo, M.A.; Costa Lima, S.A.; Reis, S. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int. J. Pharm., 2014, 477(1-2), 519-526.
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.067] [PMID: 25445970]
[147]
Ferreira, M.; Barreiros, L.; Segundo, M.A.; Torres, T.; Selores, M.; Costa Lima, S.A.; Reis, S. Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management. Colloids Surf. B Biointerfaces, 2017, 159, 23-29.http://dx.doi.org/doi:10.1016/j.colsurfb.2017.07.080
[http://dx.doi.org/10.1016/j.colsurfb.2017.07.080] [PMID: 28779637]
[148]
Ramezanli, T.; Kilfoyle, B.E.; Zhang, Z.; Michniak-Kohn, B.B. Polymeric nanospheres for topical delivery of vitamin D3. Int. J. Pharm., 2017, 516(1-2), 196-203.
[http://dx.doi.org/10.1016/j.ijpharm.2016.10.072] [PMID: 27810351]
[149]
Lapteva, M.; Santer, V.; Mondon, K.; Patmanidis, I.; Chiriano, G.; Scapozza, L.; Gurny, R.; Möller, M.; Kalia, Y.N. Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways. J. Control. Release, 2014, 196, 9-18.
[http://dx.doi.org/10.1016/j.jconrel.2014.09.021] [PMID: 25278258]
[150]
Gabriel, D.; Mugnier, T.; Courthion, H.; Kranidioti, K.; Karagianni, N.; Denis, M.C.; Lapteva, M.; Kalia, Y.; Möller, M.; Gurny, R. Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis. J. Control. Release, 2016, 242, 16-24.
[http://dx.doi.org/10.1016/j.jconrel.2016.09.007] [PMID: 27639683]
[151]
Wadhwa, S.; Singh, B.; Sharma, G.; Raza, K.; Katare, O.P. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv., 2016, 23(4), 1204-1213.
[http://dx.doi.org/10.3109/10717544.2015.1110845] [PMID: 26592918]
[152]
Abu Hashim, I.I.; Abo El-Magd, N.F.; El-Sheakh, A.R.; Hamed, M.F.; Abd El-Gawad, A.E.H. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: Ex vivo-in vivo evaluation study. Int. J. Nanomedicine, 2018, 13, 1059-1079.
[http://dx.doi.org/10.2147/IJN.S156412] [PMID: 29503541]
[153]
Lakshmi, P.K.; Devi, G.S.; Bhaskaran, S.; Sacchidanand, S. Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and phase II studies. Indian J. Dermatol. Venereol. Leprol., 2007, 73(3), 157-161.
[http://dx.doi.org/10.4103/0378-6323.32709] [PMID: 17558046]
[154]
Prasad, V.; Chaurasia, S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis. Mater. Sci. Eng. C, 2017, 79, 168-176.
[http://dx.doi.org/10.1016/j.msec.2017.05.036] [PMID: 28629004]
[155]
Moghddam, S.R.M.; Ahad, A.; Aqil, M.; Imam, S.S.; Sultana, Y. Formulation and optimization of niosomes for topical diacerein delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis. Mater. Sci. Eng. C, 2016, 69, 789-797.
[http://dx.doi.org/10.1016/j.msec.2016.07.043] [PMID: 27612773]
[156]
Kassem, A.A.; Abd El-Alim, S.H.; Asfour, M.H. Enhancement of 8-methoxypsoralen topical delivery via nanosized niosomal vesicles: Formulation development, in vitro and in vivo evaluation of skin deposition. Int. J. Pharm., 2017, 517(1-2), 256-268.
[http://dx.doi.org/doi:10.1016/j.ijpharm.2016.12.018] [PMID: 27956194]
[157]
Zhang, Y.T.; Shen, L.N.; Zhao, J.H.; Feng, N.P. Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis. Int. J. Nanomedicine, 2014, 9, 669-678.
[http://dx.doi.org/10.2147/IJN.S57314] [PMID: 24489470]
[158]
Zhang, Y.; Xia, Q.; Li, Y.; He, Z.; Li, Z.; Guo, T.; Wu, Z.; Feng, N. CD44 assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: A new strategy for clustering drug in inflammatory skin. Theranostics, 2019, 9(1), 48-64.
[http://dx.doi.org/10.7150/thno.29715] [PMID: 30662553]
[159]
Agrawal, U.; Mehra, N.K.; Gupta, U.; Jain, N.K. Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J. Drug Target., 2013, 21(5), 497-506.
[http://dx.doi.org/10.3109/1061186X.2013.771778] [PMID: 23594093]
[160]
Jain, A.; Pooladanda, V.; Bulbake, U.; Doppalapudi, S.; Rafeeqi, T.A.; Godugu, C.; Khan, W. Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis. Nanomedicine (Lond.), 2017, 13(7), 2251-2262.
[http://dx.doi.org/10.1016/j.nano.2017.06.009] [PMID: 28647592]
[161]
Jain, A.; Doppalapudi, S.; Domb, A.J.; Khan, W. Tacrolimus and curcumin co-loaded liposphere gel: Synergistic combination towards management of psoriasis. J. Control. Release, 2016, 243, 132-145.
[http://dx.doi.org/10.1016/j.jconrel.2016.10.004] [PMID: 27725194]

Rights & Permissions Print Cite
Article Metrics
42
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy